Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
Here, we describe a quantitative proteomics method using the technique of stable isotope labeling by amino acids in cell culture (SILAC) to analyze the effects of HIV-1 infection on host exosomal proteomes. This protocol can be easily adapted to cells under different stress or infection conditions.
Proteomics is the large-scale analysis of proteins. Proteomic techniques, such as liquid chromatography tandem mass spectroscopy (LC-MS/MS), can characterize thousands of proteins at a time. These powerful techniques allow us to have a systemic understanding of cellular changes, especially when cells are subjected to various stimuli, such as infections, stresses, and specific test conditions. Even with recent developments, analyzing the exosomal proteome is time-consuming and often involves complex methodologies. In addition, the resultant large dataset often needs robust and streamlined analysis in order for researchers to perform further downstream studies. Here, we describe a SILAC-based protocol for characterizing the exosomal proteome when cells are infected with HIV-1. The method is based on simple isotope labeling, isolation of exosomes from differentially labeled cells, and mass spectrometry analysis. This is followed by detailed data mining and bioinformatics analysis of the proteomic hits. The resultant datasets and candidates are easy to understand and often offer a wealth of information that is useful for downstream analysis. This protocol is applicable to other subcellular compartments and a wide range of test conditions.
Many human diseases, including viral infections, are often associated with distinctive cellular processes that take place in and around the affected cells. Proteins, often acting as the ultimate cellular effectors, mediate these processes. Analysis of the proteins often can provide invaluable information as to the local environment of affected cells and help us to understand the underlying mechanism of disease pathogenesis. Among various protein analysis techniques, proteomics holds particularly great promise. As a powerful, large-scale tool, proteomics can provide a systemic understanding of cellular processes, particularly in the area of the function and interaction of proteins. Analyzing specific proteins is made simpler through the development of labeling techniques, which allow investigators to monitor the expression of cellular components, particularly proteins, in the site of investigation. Although many proteomic analyses have been performed at cellular proteome scale, proteomic characterizations on subcellular compartments have proved to be particularly informative1. This is exemplified well in the studies of HIV-1 infection.
Exosomes, 30-100 nm membrane vesicles secreted by a wide range of cell types2,3, are critical components of intercellular communication and molecular transport. They were previously discovered to play important roles in the HIV-1 budding process4,5. By combining proteomic analysis with functional dissection, we found that exosomes released from HIV-1 infected cells are composed of a unique and quantitatively different protein signature and harbor regulatory molecules that impact cellular properties on neighboring receptive cells, including cellular apoptosis and proliferation6. The methods are described in this protocol, namely SILAC (stable isotope labeling by amino acids in cell culture)7 based proteomic characterization of exosomes from HIV-1 infected cells. Similar approaches can be applied to better understand other subcellular compartments during pathogenesis by adjusting the experimental stress to the specific compartment or fraction of interest and making necessary changes to the described procedures.
Given the recent development of quantitative proteomic methods, there are many to choose from when selecting the most efficient method for a particular experiment. Among these are the chemical-based iTRAQ (isobaric tags for relative and absolute quantification)8 and the label-free MRM (multiple reaction monitoring)9 techniques. Both methods are powerful tools and are good choices for specific settings. For a typical laboratory mainly working with cell lines, however, these two methods have relatively higher costs and are more time-consuming when compared to the SILAC based method. SILAC is a metabolic based labeling technique that incorporates nonradioactive isotopic forms of amino acids from the culture media into cellular proteins. Typically, SILAC experiments start with two cell populations, for example, infected and uninfected. Each is differentially labeled in its specific isotopic environment until full labeling is achieved. The labeled exosomes of these cells are then subjected to protein extraction. Once extracted, the labeled exosomal proteins are analyzed using liquid chromatography tandem mass spectroscopy10. Finally, the mass spectrometry results and significantly labeled proteins are subjected to statistical and bioinformatics analyses as well as rigorous biochemical verification. Our previous investigative reports suggest that the SILAC/exosome procedures are more appropriate for cell lines than primary cells, as cell lines are usually in an active proliferating state for efficient isotopic labeling,
1. Cell Culture and HIV-1 Infection
NOTE: Before starting experiments, it is recommended to check the cells' viability through Trypan Blue staining11 and their proliferation through a MTT assay12. It is also critical to use newly prepared SILAC medium. Various cell lines can be used, as long as they are in an actively proliferative stage, and are susceptible to HIV-1 infection, or the test condition of choice. In this protocol, use H9 cell line as the example.
2. Exosome Isolation
NOTE: Through a series of ultracentrifugation steps, exosomal fractions from culture supernatants are enriched15. Perform all the following steps at 4 °C, with an ultracentrifuge rotor that can reach a speed of at least 100,000 x g.
3. Protein Extraction and Preparation
4. Western Blotting Verification
NOTE: Western blotting is recommended to verify mass spectrometry results.
5. Proteomic Data Analysis
NOTE: The data quality assessment, data pretreatment, calculation and determination of significant protein candidates are done separately for each MS replicate. Once above analyses are completed, the analyzed data from replicates are compared and combined6,20,21.
6. Bioinformatics Verification and Characterization
NOTE: Existing genomic and bioinformatic information offers a wealth of information for almost every protein. Data mining and bioinformatics analysis on that information can help in gaining a great deal of insight into the property and functions of the significant candidates. This process is usually necessary to design proper downstream wet-lab experiments.
Figure 1A is a flowchart outlining the SILAC labeling procedure21. In order to purify the exosomes, the samples must be spun down via centrifuge. Figure 1B shows the steps of exosome purification by serial ultracentrifugation21. Once purified, the exosomes are subject to experimental proteomic analysis as outlined in the procedure.
Fi...
In the procedures described in this paper, we demonstrated the application of the SILAC technique to investigate the effect of HIV-1 infection on the host exosomal proteome. Initially, uninfected and HIV-1 infected cells are differentially isotope-labeled. The differentially labeled exosomes are then purified before performing protein extraction. Next, liquid chromatography-tandem mass spectrometry is employed to analyze the exosomal proteome. Finally, the resulting mass spectrometry data and potential candidate proteins...
The authors have declared no conflict of interest.
This work was supported by an ARRA supplement to the Lifespan/Tufts/Brown CFAR, P30AI042853-13S1, NIH P20GM103421, P01AA019072, R01HD072693, and K24HD080539 to BR. This work was also supported by Lifespan Pilot Research Fund (#701- 5857), Rhode Island Foundation Medical Research Grant (#20133969), and NIH COBRE URI/RIH Pilot Research Grant (P20GM104317) to ML. We thank James Myall and Vy Dang for help with the manuscript and figure preparation.
Name | Company | Catalog Number | Comments |
H9 cell line | ATCC | HTB-176 | |
Trypan Blue | Thermo Fisher | 15250061 | |
MTT assay kit | Thermo Fisher | V13154 | |
Dialyzed fetal bovine serum (FBS) | Thermo Fisher | 26400044 | |
SILAC Protein Quantitation Kit – RPMI 1640 | Thermo Fisher | 89982 | DMEM version (89983) |
L-Arginine-HCl, 13C6, 15N4 for SILAC | Thermo Fisher | 88434 | |
L-Lysine-2HCl, 13C6 for SILAC | Thermo Fisher | 88431 | |
HIV-1 NL4-3 | NIH AIDS Reagent Program | 2480 | |
Alliance HIV-1 p24 Antigen ELISA kit | PerkinElmer | NEK050001KT | |
Refrigerated super-speed centrifuge | Eppendorf | 22628045 | |
Refrigerated ultracentrifuge | Beckman Coulter | 363118 | Should be able to reach 100,000 x g |
50 mL Conical Centrifuge Tubes | Thermo Fisher | 14-432-22 | |
Ultracentrifuge Tubes | Beckman Coulter | 326823 | |
SW 32 Ti Rotor | Beckman Coulter | 369694 | |
RIPA buffer | Thermo Fisher | 89900 | |
Protease Inhibitor Cocktails | Thermo Fisher | 78430 | |
ThermoMixer | Eppendorf | 5384000020 | |
BCA Protein Assay Kit | Thermo Fisher | 23250 | |
Spectrophotometer | Biorad | 1702525 | |
SDS PAGE Gel apparatus | Thermo Fisher | EI0001 | |
Novex 4-20% Tris-Glycine Mini Gels | Novex | XV04200PK20 | |
Gel staining reagent | Sigma Aldrich | G1041 | |
Sequencing Grade Modified Trypsin | Promega | V5111 | |
SpeedVac Concentrator | Thermo Fisher | SPD131DDA | |
Antibody to human annexin A5 | Abcam | ab14196 | |
Antibody to human lactate dehydrogenase B chain | Abcam | ab53292 | |
Graphing and Statistical Software | Systat | SigmaPlot | Or GraphPad Prism |
Quantitative proteomics software suite | Max Planck Institue of Biochemistry | Maxquant | |
Software and databases | Various vendors | Refer to main text for details |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone